elacridar has been researched along with masitinib in 1 studies
| Studies (elacridar) | Trials (elacridar) | Recent Studies (post-2010) (elacridar) | Studies (masitinib) | Trials (masitinib) | Recent Studies (post-2010) (masitinib) |
|---|---|---|---|---|---|
| 284 | 8 | 119 | 127 | 18 | 104 |
| Protein | Taxonomy | elacridar (IC50) | masitinib (IC50) |
|---|---|---|---|
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 2.5 | |
| Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | 0.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
1 other study(ies) available for elacridar and masitinib
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |